Brief: OSE, Boehringer Update On SIRPα Antagonist Monoclonal Antibody Trial

Ose Immunotherapeutics SA

03/05/2022 17:08

May 3 (Reuters) - OSE IMMUNOTHERAPEUTICS SA  OSE.PA :
    * BOEHRINGER INGELHEIM AND OSE IMMUNOTHERAPEUTICS ANNOUNCE
FIRST
PATIENT DOSED IN A PHASE 1 EXPANSION TRIAL OF SIRPΑ ANTAGONIST
MONOCLONAL ANTIBODY BI 765063, TARGETING MYELOID CELLS IN
IMMUNO-ONCOLOGY
    * INITIATION OF PHASE 1 CLINICAL EXPANSION TRIAL TRIGGERS A
EUR 10
MILLION MILESTONE PAYMENT FROM BOEHRINGER INGELHEIM TO OSE
IMMUNOTHERAPEUTICS
    * TRIAL IS BEING CONDUCTED IN ADVANCED HEPATOCELLULAR
CARCINOMA
AND HEAD AND NECK CANCER PATIENTS IN COMBINATION IN PARTICULAR
WITH ANTI-PD-1 ANTIBODY EZABENLIMAB

Source text for Eikon:  ID:nBw2YLmz8a 
Further company coverage:  OSE.PA 

 (Gdansk Newsroom)
 ((Gdansk.newsroom@thomsonreuters.com; +48 58 772 09 20;))